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424 F.J. Veithanticipated from the literature. Irrespective of the reports
of the good outcomes after endovascular repair from single
expert centres or administrative databases, all these
results are heavily confounded by patient selection and
risks are under-reported. We need better evidence to
guarantee the best outcomes for future patients with
aneurysm rupture. We need to know whether an attempt at
endovascular repair would be beneficial for all patients. It
is only such knowledge that will drive changes in the
provision of healthcare services to benefit future patients.
The front cover of the Lancet issue of 26th September 2009,
which published the IDEAL statements, carried this sen-
tence: “It is incumbent on academic surgeons worldwide to
transform what was once considered a comic opera into
a dynamic world-class specialty”. We need to assess
surgical innovations, including endovascular repair for
ruptured aneurysm, rapidly in large, pragmatic RCTs.
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Part Two: Against the Motion 425Endovascular repair of a ruptured abdominal aortic
aneurysm (RAAA) was first performed successfully by Marin,
Veith et al. on April 21, 1994.1 Another case was first
reported by Yusuf, Hopkinson et al. in 1994.2 Since then
many centres have employed endovascular aneurysm repair
(EVAR) to treat RAAAs with varying results.3e13 Several
groups have developed standardised systems of manage-
ment in the RAAA setting, have used EVAR whenever
possible and have achieved good results with EVAR.3e10 In
contrast other authors have used EVAR for RAAAs more
selectively and have reported no better results with EVAR
than with traditional open repair (OR).11e13
On the basis of these many reports, it is fair to say that
the comparative efficacy of EVAR and open repair for RAAAs
is controversial and that randomised, prospective compar-
ative trials of the two treatment methods are needed with
this entity. This article will show why this is not the case
and why there is sufficient evidence without such trials to
show that all RAAAs with anatomy suitable for EVAR should
be treated in this way.
Theoretical considerations
EVAR has been used increasingly to treat patients with
RAAAs and offers many theoretical advantages over OR. It is
less invasive, eliminates damage to periaortic and abdom-
inal structures, decreases bleeding from surgical dissec-
tion, minimizes hypothermia and lessens the requirement
for deep anesthesia. Because of these potential advantages
and reports of lower procedural mortality, EVAR has been
deemed superior to OR for the treatment of RAAAs.3e10
Collected world experience with EVAR for
RAAAs
Between July 1, 2002 and January 15, 2009 data were
collected from 49 centres around the world performing
EVAR for RAAAs. Some of these data were from 13 centres
that were committed to EVAR and performed this proce-
dure on all or almost all RAAAs in patients who had suitable
aortic neck and iliac artery anatomy for EVAR. The data
from these 13 centres were updated to January 15, 2009.5
The overall collected data with the use of EVAR to treat
1037 patients with a RAAA or a ruptured aortoiliac aneu-
rysm show an overall 30-day mortality of 21.2%. This 30-day
mortality is clearly less than that of OR for RAAAs as
reported in multiple studies which ranges from 35 to 55%.14
However, in the collected experience many of the centres
limited the use of EVAR to “stable” RAAA patients or even
those with “contained” ruptures. Since hemodynamic
instability is associated with a higher risk of procedural
mortality,6,8,14 it is invalid to compare the lower procedural
EVAR mortality rates with those for OR.
Because of this, the updated outcomes for EVAR were
examined in the selected group of 13 centres that were
committed to performing EVAR to treat all RAAA patients
who were anatomically suitable for endograft treatment,
including those that were hemodynamically unstable and
those in profound shock.5 These centres were usually the
ones with the larger experience. Although there was somevariability in the approach of these centres to the treat-
ment of RAAA patients, most had some degree of stan-
dardization and many had a defined protocol. All were
experienced in the use of EVAR and endovascular adjuncts
for elective abdominal aneurysm treatment and all had
dedicated endovascular facilities and imaging equipment.
Despite the use of EVAR to treat almost all anatomically
suitable RAAA patients, the 30-day mortality for EVAR in
680 patients was a favorable 19.7% with a range of 0e32%.5
These same 13 centres performed open repair for RAAAs
in 763 patients who had anatomy unsuitable for EVAR during
this same period. In those 763 patients the 30-day mortality
for OR was 36.3% with a range of 8e49% (p < 0.0001 for
EVAR vs OR).5
These updated comparative outcome results (30-day
mortality 19.7% for EVAR vs 36.3% for OR from these 13
centres committed to EVAR treatment of all possible RAAAs
strongly suggest that EVAR is a superior way to treat RAAAs
in those patients who have aortic neck and iliac anatomy
suitable for endovascular graft treatment. Additional proof
that EVAR is a better treatment for some RAAA patients is
that many patients (10e15%) in this collected experience
who were categorically unsuitable or prohibitively high risk
for OR survived for many years after EVAR.5
Reasons for variable results with EVAR for
RAAAs
There are several possible reasons which might explain the
discordant results for RAAA treatment by EVAR reported by
different authors.3e13 Among these reasons are the impor-
tance of several strategies, adjuncts, and technical factors
which are thought to influence the outcome of EVAR treat-
ment for RAAAs, and which probably account for the favor-
able EVAR outcomes in the 13 centres in the collected
experience committed to perform EVAR whenever possible:5
1. Standard approach or protocol. These allow the most
effective decision making and treatment of these
patients in what are often confusing and stressful
circumstances.9,10
They are also important to facilitate education in and
recognition of RAAAs by generalists, emergency room
personnel and others to enable early diagnosis and mobili-
zation of the specialised care givers best trained to opti-
mize treatment.
2. Fluid restriction (Hypotensive Hemostasis). Fluid
resuscitation should be restricted even if the patient
becomes hypotensive. Experience has shown that
systolic arterial pressures of 50e70 mm Hg are well
tolerated for short periods and limit internal bleeding
and its associated loss of platelets and clotting
factors.4e6,10,15 Whether or not pharmacological
lowering of blood pressure is beneficial remains to be
conclusively shown.6,10
3. Treatment site. EVAR procedures are optimally per-
formed in a site equipped for excellent fluoroscopic
imaging and open surgery since some patients will
require OR or open adjuncts to their EVAR.
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latter should be obtained percutaneously under local
anesthesia. This permits arteriography to define aortic
and arterial anatomy, facilitates large sheath and
supraceliac balloon placement if needed, and prevents
circulatory collapse caused by the induction of general
anesthesia. Whether general anesthesia is used later to
eliminate motion and improve fluoroscopic imaging to
permit precise graft deployment remains controversial.
One group has successfully used local anesthesia
supplemented by sedation throughout as an
alternative.3,6,10
5. Supraceliac aortic sheath placement and balloon
control. Most groups favor their use only when there
is severe circulatory collapse. In such cases, defla-
tion of the balloon before sealing of the rupture site
will result in immediate recurrence of the circula-
tory collapse. Therefore, techniques have been
developed to maintain continuous aortic control
until the endograft has sealed the leak.4e6,10,16,17
These techniques use multiple balloons to minimize
renal and visceral ischaemia by placing secondary
balloons within the endograft as the supraceliac
balloon is deflated and removed through its sup-
porting sheath.
6. Endograft type and configuration. Both bifurcated and
aortouni-iliac (or femoral) grafts can be used success-
fully, although some patients have unilateral iliac
disease which mandates a unilateral configuration.
Modular and unibody grafts have been used successfully
in both configurations. An appropriate inventory of
suitable grafts and accessories must be stocked sterile
in the treatment site and be available for the procedure
and unexpected contingencies.
7. Abdominal compartment syndrome is a major cause of
morbidity and mortality after EVAR for RAAA. It is
advantageous to keep a high index of suspicion for this
entity. Laparotomy and hematoma evacuation have
alleviated the hypotension, high ventilatory compliance
and oliguria that occurs with the full blown syndrome.
Monitoring bladder pressure has been helpful in the
early detection of the syndrome,6,10 and early lapa-
rotomy with open abdomen treatment (OAT) and
suction/sponge (VAC) dressings may decrease mortality
and allow survival in otherwise hopeless circumstances
when small bowel and mesenteric edema cause loss of
domain for the abdominal viscera.10,18
8. EVAR for worst risk patients. It is probable that EVAR is
most beneficial in augmenting survival when it is used in
the worst risk patients who are unlikely to survive an
OR. Patients with hemodynamic instability and
profound circulatory collapse, a hostile abdomen, or
those unable to receive transfusion would fall in this
category. If such patients, particularly those that are
hemodynamically unstable, are excluded from EVAR, it
is likely that the improved survival that can accrue from
this form of treatment will be diminished.5
The reduced 30-day mortality after EVAR (19.7%)
compared to patients treated by OR (36.3%) together with
the ability to obtain survival in many RAAA patients who
were prohibitive risks for OR constitute strong evidencethat EVAR is a better way to treat RAAAs in at least some
patients, provided the described strategies, adjuncts and
techniques are employed.
Thus, in response to the question: Is there a need for
a randomised controlled comparison of EVAR and OR in
RAAA patients, it is clear the answer is no. The data from
the collected experience in many centres5 suggest that one
is not needed. If those who believe such evidence is
necessary to confirm the value of EVAR in the RAAA setting
wish to perform such trials, these results are awaited with
interest. However, such studies will be difficult to perform,
and many believe such studies will be unnecessary and
unethical in view of the experience that has thus far been
obtained in this morbid and life-threatening condition.
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EDITORS’ COMMENT
Trans-Atlantic Debate: Is a
Randomised Trial Necessary to
Determine Whether Endovascular
Repair is the Preferred Management
Strategy in Patients with Ruptured
Abdominal Aortic Aneurysms?J.-B. Ricco a,*, T.L. Forbes ba Section Editor. European Journal of Vascular and
Endovascular Surgery
b Section Editor. Journal of Vascular Surgery, London,
Ontario, Canada
Given the poor outcomes after open repair (OR) for
ruptured abdominal aortic aneurysms (RAAA), as well as the
low 30-day mortality associated with endovascular aorticDOI of original article: 10.1016/j.ejvs.2010.06.022, 10.1016/
j.ejvs.2010.06.005
* Corresponding author. J.-B. Ricco, MD, PhD, Vascular Surgery
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France
E-mail address: jbricco2@mac.com (J.-B. Ricco).repair (EVAR) in elective patients, an increasing number of
centers have established protocols to use EVAR for RAAA
(REVAR).
In this debate, Frank Veith defends the motion that
there is no need for a randomised controlled trial (RCT) as
there is sufficient evidence to show that RAAAs with
appropriate anatomy should be treated endovascularly. In
fact, by 2005 up to 17% of RAAAs were treated endovasc-
ularly in the United States.1 However in many of these
pioneering centers that reported excellent results with
REVAR, patients continue to undergo OR between 53% and
64% of the time.2 In addition, the proportion of RAAA’s
anatomically suitable for REVAR is between 47% and 67%,3
somewhat limiting the applicability of the endovascular
technique in this setting. Dr. Veith’s summary of the world
experience goes a long way to prove that endovascular
repair is the preferred treatment in centers such as New
York, Albany, Seattle, Calgary, and Malmo, and others with
the appropriate experience, protocols and infrastructure.
However, how generalizable are these results to other
centers without this experience? Can all patients expect
the same results as those lucky enough to have been
treated at these centers?
Janet Powell and Robert Hinchliffe have a different view
and consider the need for further evidence to support
widespread adoption and funding of REVAR by healthcare
policy makers. They argue that the only evidence available
now about the benefits of REVAR comes from systematic
reviews of cohort studies with poor adjustments for
confounders. In fact the only pilot RCT shows comparable
30-day mortality in patients undergoing REVAR and
OR. They defend a pragmatic RCT, including unstable
patients, with the clinical diagnosis of RAAA at the point of
randomization to undergo immediate CT-scan with REVAR
whenever possible or OR, in which case a CT-scan is
optional.
Difficulties of such a study are evident and include
selection of centers of expertise, effect of patient
transfer on outcomes,4 instant accessibility of a CT-
scanner and an operating room dedicated to EVAR at all
times, informed consent in hemodynamically unstable
patients, anaesthetic expertise using a structured
protocol with hypotensive hemostasis, endovascular and
surgical expertise available anytime, availability of
a large choice of stent-grafts, use of aortic balloon
occlusion in hemodynamically unstable patients, access
to critical care facilities and surveillance for abdominal
compartment syndrome. Although not insurmountable,
some of these factors will complicate the operation and
interpretation of this RCT, and likely lengthen its
recruitment period.
In summary, both parties agreed that endovascular
repair of RAAA saves lives, but they differ when considering
the applicability of EVAR in these emergency situations.
Frank Veith maintains that we have enough clinical
evidence to use REVAR in the subset of patients with
favorable anatomy. Janet Powell and Robert Hinchliffe feel
that an RCT is required to obtain more generalizable
information. Either way the introduction of endovascular
repair of RAAAs has been an exciting and life saving inno-
vation and we await further information regarding its use
and applicability, randomised or not.
